masteron side effects
Safety and effectiveness of Tevagrastim drug first used in patients with before the age of 55 years without cytogenetic abnormalitiesmasteron side effects have not been established.
Patients with osteoporosis, which developed as a result of the disease of bone, long-term (more than 6 months) use drug is recommended to regularly monitor bone density.
There are rare reports of undesirable adverse reactions on the part of the respiratory system in the application of G-, in particular interstitial pneumonia. Patients who have recently undergone infiltrative pulmonary disease or pneumonia may be at high risk. The appearance of symptoms such as cough, fever and shortness of breath on the background of pulmonary infiltrates revealed by examination, and signs of decline in lung function may be the first signs of use the drug is stopped and conduct appropriate therapy
It reported on the development of the syndrome of increased permeability of the capillaries in the application , which is accompanied by a decrease in blood pressure, hypoalbuminemia, edema and haemoconcentration. It is necessary to monitor the status of patients who develop the syndrome of increased permeability of the capillaries, to carry out symptomatic treatment and resuscitation, if necessary.
Precautions for patients with cancer and diseases
A small number of patients (less than 5%) treated with filgrastim at doses higher per day, there was leukocytosis masteron side effects. Side effects directly attributable to filgrastim induced leukocytosis, are not described. However, given the potential risks associated with leukocytosis, during treatment with filgrastim should be regular monitoring of white blood cell count. If, after passing the minimum expected it to exceed , filgrastim should be discontinued immediately. In the case of filgrastim for the mobilization of hematopoietic stem cells, the drug should be abolished when the leukocyte count exceeds .
The risk associated with high-dose chemotherapy
Special caution should be exercised in patients receiving high-dose chemotherapy, because higher doses of chemotherapy have a more severe toxicity, including skin reactions and masteron side effects side effects to the cardiovascular, nervous and respiratory systems (sm. specific instructions for use chemical preparations).
Monotherapy filgrastim did not prevent the development of thrombocytopenia and anemia due to myelosuppressive chemotherapy. Because of the potential application of higher doses of chemotherapy (eg full doses in accordance with the schemes), the patient may be at greater risk of developing thrombocytopenia and anemia. It is recommended to regularly twice a week to carry out blood tests to determine the platelet count and hematocrit in the application of filgrastim after chemotherapy. Particular caution should be exercised when using single-component or combination chemotherapeutic regimens known to cause severe thrombocytopenia. In the application of filgrastim for the mobilization of masteron side effects it was identified decrease the severity and duration of thrombocytopenia caused by myelosuppressive chemotherapy or myeloblastic.